Clinical Trial Update: A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

View source ↗

Summary

Pfizer's post-marketing surveillance study of Zirabev to assess safety and effectiveness in domestic cancer patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Colorectal Cancer
• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Non-small Cell Lung Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• ZIRABEV (BEVACIZUMAB-BVZR)

Snippet

Sponsor: Pfizer | Conditions: Non-small Cell Lung Cancer, Metastatic Colorectal Cancer | Status: WITHDRAWN